Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

international flavors & fragrances inc. - IFF

IFF

Close Chg Chg %
70.69 0.07 0.10%

Open Market

70.76

+0.07 (0.10%)

Volume: 776.02K

Last Updated:

Mar 26, 2026, 3:38 PM EDT

Trade Now

Company Overview: international flavors & fragrances inc. - IFF

IFF Key Data

Open

$70.46

 Day Range

70.23 - 71.81

52 Week Range

59.14 - 84.22

 Market Cap

$18.06B

Shares Outstanding

255.48M

 Public Float

250.85M

Beta

1.01

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.36

Yield

226.28%

 Dividend

$0.40

EX-DIVIDEND DATE

Mar 20, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.90M

  

IFF Performance

1 Week
 
 6.14%
 
1 Month
 
 -14.01%
 
3 Months
 
 4.80%
 
1 Year
 
 -7.54%
 
5 Years
 
 -49.68%
 

IFF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About international flavors & fragrances inc. - IFF

International Flavors & Fragrances, Inc. engages in the manufacture and supply of flavors and fragrances used in the food, beverage, personal care, and household products industries. It operates through the following segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. The Nourish segment consists of legacy Taste segment combined with N&B's Food & Beverage division and the food protection business of N&B's Health & Biosciences division. The Health & Biosciences business consists of a biotechnology-driven portfolio of enzymes, food cultures, probiotics and specialty ingredients for food, home and personal care, and health and wellness applications. The Scent business creates fragrance compounds, fragrance ingredients and cosmetic ingredients that are integral elements in the world’s finest perfumes and best-known household and personal care products. The Pharma Solutions business produces a vast portfolio including cellulosics and seaweed-based pharma excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling. The company was founded in 1833 and is headquartered in New York, NY.

IFF At a Glance

International Flavors & Fragrances, Inc.
521 West 57th Street
New York, New York 10019-2960
Phone 1-212-765-5500 Revenue 10.89B
Industry Food: Specialty/Candy Net Income -361,000,000.00
Sector Consumer Non-Durables Employees 21,500
Fiscal Year-end 12 / 2026
View SEC Filings

IFF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.584
Price to Book Ratio 1.217
Price to Cash Flow Ratio 20.30
Enterprise Value to EBITDA 11.24
Enterprise Value to Sales 2.144
Total Debt to Enterprise Value 0.285

IFF Efficiency

Revenue/Employee 506,511.628
Income Per Employee -16,790.698
Receivables Turnover 5.442
Total Asset Turnover 0.402

IFF Liquidity

Current Ratio 1.422
Quick Ratio 0.821
Cash Ratio 0.15

IFF Profitability

Gross Margin 30.937
Operating Margin 10.239
Pretax Margin -3.783
Net Margin -3.315
Return on Assets -1.332
Return on Equity -2.576
Return on Total Capital -1.735
Return on Invested Capital -1.742

IFF Capital Structure

Total Debt to Total Equity 46.99
Total Debt to Total Capital 31.968
Total Debt to Total Assets 26.043
Long-Term Debt to Equity 37.396
Long-Term Debt to Total Capital 25.441
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for International Flavors & Fragrances Inc. - IFF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
12.44B 11.48B 11.48B 10.89B
Sales Growth
+6.73% -7.73% +0.04% -5.17%
Cost of Goods Sold (COGS) incl D&A
9.02B 8.48B 7.97B 7.52B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.18B 1.14B 1.01B 962.00M
Depreciation
452.00M 462.00M 405.00M 394.00M
Amortization of Intangibles
727.00M 680.00M 610.00M 568.00M
COGS Growth
+4.17% -5.94% -5.99% -5.66%
Gross Income
3.42B 3.00B 3.51B 3.37B
Gross Income Growth
+14.10% -12.41% +17.11% -4.07%
Gross Profit Margin
+27.52% +26.13% +30.58% +30.94%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.28B 2.17B 2.33B 2.25B
Research & Development
603.00M 636.00M 671.00M 694.00M
Other SG&A
1.67B 1.53B 1.66B 1.56B
SGA Growth
+7.97% -4.79% +7.56% -3.34%
Other Operating Expense
- - - -
-
Unusual Expense
2.47B 2.96B 595.00M 857.00M
EBIT after Unusual Expense
(1.32B) (2.12B) 585.00M 258.00M
Non Operating Income/Expense
33.00M (14.00M) (2.00M) (441.00M)
Non-Operating Interest Income
- - 15.00M 19.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
336.00M 380.00M 305.00M 229.00M
Interest Expense Growth
+16.67% +13.10% -19.74% -24.92%
Gross Interest Expense
336.00M 380.00M 305.00M 229.00M
Interest Capitalized
- - - -
-
Pretax Income
(1.63B) (2.52B) 278.00M (412.00M)
Pretax Income Growth
-559.04% -54.95% +111.04% -248.20%
Pretax Margin
-13.06% -21.94% +2.42% -3.78%
Income Tax
239.00M 45.00M 31.00M (53.00M)
Income Tax - Current - Domestic
151.00M 55.00M (49.00M) (174.00M)
Income Tax - Current - Foreign
325.00M 359.00M 384.00M 391.00M
Income Tax - Deferred - Domestic
(188.00M) (81.00M) (227.00M) (160.00M)
Income Tax - Deferred - Foreign
(49.00M) (288.00M) (77.00M) (110.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - 3.00M 2.00M
-
Consolidated Net Income
(1.86B) (2.56B) 247.00M (359.00M)
Minority Interest Expense
7.00M 4.00M 4.00M 2.00M
Net Income
(1.87B) (2.56B) 243.00M (361.00M)
Net Income Growth
-797.01% -37.31% +109.47% -248.56%
Net Margin Growth
-15.02% -22.35% +2.12% -3.31%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(1.87B) (2.56B) 243.00M (361.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(1.87B) (2.56B) 243.00M (361.00M)
EPS (Basic)
-7.3255 -10.0588 0.9492 -1.4102
EPS (Basic) Growth
-764.20% -37.31% +109.44% -248.57%
Basic Shares Outstanding
255.00M 255.00M 256.00M 256.00M
EPS (Diluted)
-7.3255 -10.0588 0.9492 -1.4102
EPS (Diluted) Growth
-764.20% -37.31% +109.44% -248.57%
Diluted Shares Outstanding
255.00M 255.00M 256.00M 256.00M
EBITDA
2.33B 1.97B 2.19B 2.08B
EBITDA Growth
+13.57% -15.18% +11.25% -5.38%
EBITDA Margin
+18.70% +17.19% +19.11% +19.07%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 92.667
Number of Ratings 21 Current Quarters Estimate 1.076
FY Report Date 03 / 2026 Current Year's Estimate 4.441
Last Quarter’s Earnings 0.80 Median PE on CY Estimate N/A
Year Ago Earnings 4.20 Next Fiscal Year Estimate 4.805
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 18 16
Mean Estimate 1.08 1.17 4.44 4.80
High Estimates 1.11 1.24 4.87 5.37
Low Estimate 1.04 1.12 4.15 4.49
Coefficient of Variance 2.29 2.99 3.44 5.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 10
OVERWEIGHT 3 3 6
HOLD 6 6 5
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for International Flavors & Fragrances Inc. - IFF

Date Name Shares Transaction Value
May 20, 2025 Stephen N. Landsman EVP, General Counsel 12,000 Open market or private purchase of non-derivative security Non-derivative transaction at $77.58 per share 930,960.00
May 20, 2025 Beril Yildiz CAO, SVP & Controller 3,321 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $77.34 per share 256,846.14
May 20, 2025 Stephen N. Landsman EVP, General Counsel 10,000 Open market or private purchase of non-derivative security Non-derivative transaction at $77.22 per share 772,200.00
Apr 8, 2025 Deborah Borg EVP, Chief Ppl&Culture Officer 25,436 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 1,859,880.32
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 6,206 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 9,553 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 698,515.36
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 10,132 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 740,851.84
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 10,362 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Angela Strzelecki President, Pharma Solutions 9,859 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Deborah Borg EVP, Chief Ppl&Culture Officer 32,883 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Deborah Borg EVP, Chief Ppl&Culture Officer 27,981 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 12,213 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 13,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 9,485 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 693,543.20
Apr 8, 2025 Michael DeVeau CFO 9,947 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.12 per share 727,324.64
Apr 8, 2025 Michael DeVeau CFO 10,204 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Michael DeVeau CFO 9,492 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 7, 2025 Ana Paula Mendonça President, Scent 452 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.64 per share 39,161.28
Apr 7, 2025 Ana Paula Mendonça President, Scent 6,884 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

International Flavors & Fragrances Inc. in the News